Astria Therapeutics, Inc. ( ATXS ) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics (ATXS) delivered earnings and revenue surprises of -34.15% and -95.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BioCryst ( BCRX ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, Nov. 3, 2025 at 8:30 a.m. ETChief Executive Officer - John StonehouseContinue reading ...
HALPER SADEH LLC ENCOURAGES PLYM, HOLX, ATXS, PCH SHAREHOLDERS to Contact the Firm to Discuss Their Rights - Astria Therapeutics ( NASDAQ:ATXS ) , Hologic ( NASDAQ:HOLX )
NEW YORK, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. ( Nasdaq - SOHO ) , Hologic, Inc. ( Nasdaq - HOLX ) , Astria Therapeutics, Inc. ( Nasdaq - ATXS ) , PotlatchDeltic Corporation ( Nasdaq - PCH )
BALA CYNWYD, Pa., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. ( Nasdaq - HOLX ) , TrueCar, Inc. ( Nasdaq - TRUE ) , Astria Therapeutics, Inc. ( Nasdaq - ATXS ) , PotlatchDeltic Corporation ( Nasdaq - PCH )
BALA CYNWYD, Pa., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders - Astria Therapeutics ( NASDAQ:ATXS ) , Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. ( Nasdaq - TRUE ) , Astria Therapeutics, Inc. ( Nasdaq - ATXS ) , PotlatchDeltic Corporation ( Nasdaq - PCH ) , SWK Holdings Corporation ( Nasdaq - SWKH )
BALA CYNWYD, Pa., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
This Verisk Analytics Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Astria Therapeutics ( NASDAQ:ATXS ) , Atmos Energy ( NYSE:ATO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
BioCryst ( BCRX ) Soars 6.1%: Is Further Upside Left in the Stock?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings - Astria Therapeutics ( NASDAQ:ATXS ) , Citigroup ( NYSE:C )
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Tuesday. The Dow traded up 0.72% to 46,399.60 while the NASDAQ fell 0.17% to 22,656.09. The S&P 500 also rose, gaining, 0.26% to 6,672.03. Industrials shares jumped by 1.4% on Tuesday.
Why Is BioCryst Pharmaceuticals Stock Trading Lower Today? - Astria Therapeutics ( NASDAQ:ATXS ) , BioCryst Pharma ( NASDAQ:BCRX )
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) on Tuesday agreed to acquire Astria Therapeutics, Inc. ( NASDAQ:ATXS ) for a mix of cash and stock. The deal represents an implied value of $13 per Astria share, and approximately $700 million in enterprise value.
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday - American Resources ( NASDAQ:AREC ) , Albertsons Companies ( NYSE:ACI )
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Tuesday. Shares of Domino's Pizza, Inc. ( NYSE:DPZ ) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
- Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE portfolio over the next decade -
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - Astria Therapeutics ( NASDAQ:ATXS ) , BioCryst Pharma ( NASDAQ:BCRX )
- Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE portfolio over the next decade -
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
- Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio ...
All You Need to Know About Astria Therapeutics ( ATXS ) Rating Upgrade to Buy
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Astria Therapeutics ( ATXS ) Could Rally 294.75%: Here's is How to Trade
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Astria Therapeutics, Inc. ( ATXS ) Now Trades Above Golden Cross: Time to Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Does Astria Therapeutics ( ATXS ) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - ADS-TEC Energy ( NASDAQ:ADSE ) , AngioDynamics ( NASDAQ:ANGO )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Limoneira Company LMNR fell sharply in today's pre-market trading after reporting fourth-quarter results.
Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Astria Therapeutics ( NASDAQ:ATXS ) , ARM Holdings ( NASDAQ:ARM )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Monday. Shares of Arm Holdings plc ARM fell sharply in today's pre-market trading after a US jury reportedly found Qualcomm QCOM did not breach Nuvia's license agreement with the company.
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - American Battery Tech ( NASDAQ:ABAT )
Shares of Rumble Inc. RUM rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.
Is Astria Therapeutics ( ATXS ) Stock Outpacing Its Medical Peers This Year?
Here is how Astria Therapeutics, Inc. (ATXS) and Abbott (ABT) have performed compared to their sector so far this year.
Global Allergy Diagnostics and Therapeutics Market Size/Share Worth USD 78,036.1 Million by 2033 at a 8.1% CAGR: Custom Market Insights ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value )
Austin, TX, USA, Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "Allergy Diagnostics and Therapeutics Market Size, Trends and Insights By Product Type ( Instruments, Consumables, Therapeutics, Others ) , By Test Type ( Skin Tests, Blood ...
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
WATERTOWN, Mass., Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.
Is Artivion ( AORT ) Stock Outpacing Its Medical Peers This Year?
Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
Glenmark Pharma reports net loss of Rs 331 cr in Q3 FY24 | Capital Market News
Glenmark Pharma reports net loss of Rs 331 cr in Q3 FY24 Business Standard ...
Glenmark Pharma Q3 results: Standalone loss at Rs 20 cr, revenue dips 38.4% | Company Results
Glenmark Pharma Q3 results: Standalone loss at Rs 20 cr, revenue dips 38.4% Business Standard ...
Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24
MUMBAI, India, Feb. 14, 2024 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. ( Glenmark ) , a research-led, global pharmaceutical Company, today announced its financial results for the third quarter ended December 31, 2023.
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying - Astria Therapeutics ( NASDAQ:ATXS ) , InnSuites Hospitality ( AMEX:IHT )
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
As we move up the value chain, developing comprehensive portfolio for global market to be key priority: Glenn Saldanha, CMD, Glenmark Pharmaceuticals
Glenmark Pharmaceutcials is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Over the years, the pharma major has played a crucial role in discovering advance therapies.
Is a Surprise Coming for Astria Therapeutics ( ATXS ) This Earnings Season?
Astria Therapeutics (ATXS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Suncor ( SU ) Q3 Earnings Preview: What Investors Need to Know
Improvement in production and lower costs are likely to have buoyed the third-quarter earnings of Suncor Energy (SU), only to be offset by a drop in realized prices.
Will NexTier Merger Boost Patterson-UTI's ( PTEN ) Q3 Earnings?
Patterson-UTI Energy (PTEN) beat the Zacks Consensus Estimate for earnings thrice in the last four quarters and met in the other, resulting in an earnings surprise of 20.5%, on average.
Survey Results Positive for New HAE Drug
November 3, 2023 ( Investorideas.com Newswire ) Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.
Astria Therapeutics Director Trades $7.00M In Company Stock - Astria Therapeutics ( NASDAQ:ATXS )
PERCEPTIVE ADVISORS LLC, Director at Astria Therapeutics ATXS, reported a large insider buy on October 18, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that LLC purchased 1,074,608 shares of Astria Therapeutics.
Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday - Astria Therapeutics ( NASDAQ:ATXS ) , Dynatrace ( NYSE:DT )
Cantor Fitzgerald cut Hyliion Holdings Corp. HYLN price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell 1.4% to $0.6449 in pre-market trading. B of A Securities increased the price target for Target Corporation ...
Glenmark arm inks licensing pact with Astria Therapeutics
With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company's prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.
Glenmark's subsidiary Ichnos Sciences enters into licensing agreement with Astria Therapeutics for its monoclonal antibody portfolio
Ichnos Sciences, a wholly-owned subsidiary of Glenmark Pharmaceuticals, on Thursday announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing ...
Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock ( NYSE:BMY ) , SenesTech, Inc. - Common Stock ( NASDAQ:SNES )
On Wednesday, 311 stocks hit new 52-week lows. Bristol-Myers Squibb Company Common Stock BMY is the largest company in terms of market cap to set a new 52-week low this morning. SenesTech, Inc. - Common Stock SNES was the smallest company by market cap to set a new 52-week low. A10 Networks, ...
Astria ( ATXS ) Rises 5% on Fast Track Tag for Angioedema Drug
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.
Here's What Could Help Astria Therapeutics, Inc. ( ATXS ) Maintain Its Recent Price Strength
Astria Therapeutics, Inc. (ATXS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Does Astria Therapeutics, Inc. ( ATXS ) Have the Potential to Rally 70% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 70.1% in Astria Therapeutics, Inc. (ATXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Is Lantheus ( LNTH ) Outperforming Other Medical Stocks This Year?
Here is how Lantheus Holdings (LNTH) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
What Makes Astria Therapeutics, Inc. ( ATXS ) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday - AMC Entertainment ( NYSE:AMC ) , Alvotech ( NASDAQ:ALVO )
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today's session. AMC Entertainment Holdings, Inc. APE jumped 77% to $1.21. AMC Entertainment Holdings Inc AMC announced an equity capital raise and a debt for equity ...
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - Astria Therapeutics ( NASDAQ:ATXS ) , Duolingo ( NASDAQ:DUOL )
Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday - Astria Therapeutics ( NASDAQ:ATXS ) , AtriCure ( NASDAQ:ATRC )
Morgan Stanley cut VTEX VTEX price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on Friday. Keybanc cut Progyny, Inc. PGNY price target from $55 to $45.
Dow Dips Over 800 Points; S&P 500 Down 2.8% - Astria Therapeutics ( NASDAQ:ATXS ) , Crown Castle ( NYSE:CCI )
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points. The Dow traded down 2.62% to 33,077.91 while the NASDAQ fell 3.45% to 10,785.29. The S&P 500 also fell, dropping, 2.80% to 3,883.40. Also check this: DSS And 3 Other Stocks Under $1 Insiders Are ...
